How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, gender, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about abrocitinib, tralokinumab, upadacitinib

Marketing authorisation indication

2.1 Abrocitinib (Cibinqo, Pfizer) is 'indicated for the treatment of moderate-to severe-atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy'.

2.2 Tralokinumab (Adtralza, Leo) is 'indicated for the treatment of moderate to severe atopic dermatitis in adult patients who are candidates for systemic therapy'.

2.3 Upadacitinib (Rinvoq, AbbVie) is 'indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy'.

Dosage in the marketing authorisation

2.4 The dosage schedule for abrocitinib is available in the summary of product characteristics for abrocitinib.

2.5 The dosage schedule for tralokinumab is available in the summary of product characteristics for tralokinumab.

2.6 The dosage schedule for upadacitinib is available in the summary of product characteristics for upadacitinib.

Price

2.7 The list price of abrocitinib is £893.76 for a 28-pack of 100 mg or 200 mg tablets (excluding VAT, BNF online, accessed March 2022). The company has a commercial arrangement, which would have applied if the technology had been recommended.

2.8 The list price of tralokinumab is £1,070 for a 4-pack of 150 mg per 1ml pre-filled syringe (excluding VAT, BNF online, accessed March 2022). The company has a commercial arrangement, which would have applied if the technology had been recommended.

2.9 The list price of upadacitinib is £805.56 for a 28-pack of 15 mg modified-release tablets or £1,611.12 for a 28-pack of 30 mg modified-release tablets (excluding VAT, BNF online, accessed March 2022). The company has a commercial arrangement, which would have applied if the technology had been recommended.